Abstract
We examined serum NCC-ST 439 for its significance as a tumor marker of large bowel cancer in 121 patients with primary and 36 with recurrent large bowel cancer. Serum NCC-ST 439 was positive in 27.3 percent of the former and 66.7 percent of the latter. It was false-positive in only 5.6 percent of patients with benign diseases. Positive serum NCC-ST 439 correlated with lymph node and liver metastases. The combination assay for NCC-ST 439, CEA, and CA19-9 was positive in 49.6 percent of the patients with primary tumors and 88.9 percent of those with recurrent tumors; in other words, the diagnostic accuracy improved. The results demonstrated that the determination of serum NCC-ST 439 in large bowel cancer might be useful in cancer staging and that NCC-ST 439, if used in combination with CEA, is particularly useful in diagnosing recurrences because of its improved diagnostic accuracy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Thomson DM, Krupey J, Freedman SO, Gold P. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci U S A 1969;64:161–7.
Cooper MJ, Mackie CR, Skinner DB, Moossa AR. A reappraisal of the value of patients with various neoplasmas. Br J Surg 1979;66:120–3.
Goldenberg DM. Carcinoembryonic antigen in the management of colorectal cancer. Acta Hepato-Gastroenterol 1979;26:1–3.
Mach J-P, Jaeger PH, Bertholet M-M, Ruegsegger C-H, Loosli RM, Pettavel J. Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (C.E.A.). Lancet 1974;2:535–40.
Hirohashi S, Watanabe M, Shimosato Y, Sekine T. Monoclonal antibody reactive with the sialyl-sugar residue of a high molecular weight glycoprotein in sera of cancer patients. Jpn J Cancer Res 1984;75:485–8.
Watanabe M, Hirohashi S, Shimosato Y,et al. Carbohydrate antigen defined by a monoclonal antibody raised against a gastric cancer xenograft. Jpn J Cancer Res 1985;76:43–52.
Gold P, Freedman SO. Demonstration of tumorspecific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439–62.
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7.
Ohkura H, Hattori N, Miyazaki I,et al. Clinical study of the NCC-ST 439 EIA kit using serum from patients with various types of cancer and benign disease. Gan To Kagaku Ryoho 1987;14:1907–12.
Lo Gerfo P, Herter FP. Carcinoembryonic antigen and prognosis in patients with colon cancer. Ann Surg 1975;181:81–4.
Wanebo HJ, Rao B, Pinsky CM,et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978;299:448–51.
Lewi H, Blumgart LH, Carter DC,et al. Pre-operative carcino-embryonic antigen and survival in patients with colorectal cancer. Br J Surg 1984;71:206–8.
Hostetter RB, Campbell DE, Chi K,et al. Carcinoembryonic antigen enhances metastatic potential of human colorectal carcinoma. Arch Surg 1990;125:300–4.
Kamata T, Yonemura Y, Sugiyama K, Yamaguchi A, Miwa K, Miyazaki I. Monoclonal antibody NCC-ST 439 in gastric cancer tissue. Jpn J Gastroenterol Surg 1989;90:222–7.
Author information
Authors and Affiliations
About this article
Cite this article
Yamaguchi, A., Kurosaka, Y., Ishida, T. et al. Clinical significance of tumor marker NCC-ST 439 in large bowel cancers. Dis Colon Rectum 34, 921–924 (1991). https://doi.org/10.1007/BF02049709
Issue Date:
DOI: https://doi.org/10.1007/BF02049709